At Alchemab Therapeutics the first step in the drug discovery journey starts not in a laboratory but with an individual person – not a scientist or researcher, but a patient. The biotech aims to target diseases across neurology and oncology through naturally occurring protective antibodies, mining the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.
Alchemab Is Bringing A New Meaning To Patient-Centered Care
British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience
Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.
More from Innovation
As India prepares to commercialize its first advanced therapies it must engage key stakeholders to ensure successful implementation. Learning from global best practices and managing pricing strategies will be crucial to maximize access, deliver high-quality outcomes, and sustain innovation through reinvestment in R&D.
Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.
In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.
New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.
More from In Vivo
As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.
As the pharmaceutical sector evolves, the landscape of sales-driving indications is set for transformation by 2030. This article explores the therapeutic areas poised for substantial growth and examines how leading companies are strategically positioning themselves to capitalize on these emerging opportunities.
New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.